Work

Corrigendum to “Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib” [Leukemia Res. 79 (2019) 38–44]

Year: 2019

Type: erratum

Source: Leukemia Research

DOI: 10.1016/j.leukres.2019.04.006

Authors: Aaron T. Gerds, Tetsuzo Tauchi, Ellen Ritchie, Michael Deininger, Catriona Jamieson, Ruben Mesa, Mark Heaney, Norio Komatsu, Hironobu Minami, Yun Su, Naveed Shaik, Xiaoxi Zhang, Christine DiRienzo, Mirjana Zeremski, Geoffrey Chan, Moshe Talpaz

Institutions: Tokyo Medical University, Cornell University, Weill Cornell Medicine, Huntsman Cancer Institute, University of California San Diego, Moores Cancer Center, Mays Cancer Center at UT Health San Antonio, Columbia University Irving Medical Center, Juntendo University, Kobe University Hospital, Pfizer (United States), University of Michigan, U-M Rogel Cancer Center

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Award: Mays Cancer Center at UT Health SA

OpenAlex ID: W2941727860

Cites:

Cited by: 1

Related to: 10